Prelude Therapeutics (PRLD) to Release Quarterly Earnings on Thursday

Prelude Therapeutics (NASDAQ:PRLD) is anticipated to post its quarterly earnings results before the market opens on Thursday, February 20th. Analysts expect Prelude Therapeutics to post earnings of ($0.48) per share for the quarter.

Prelude Therapeutics Trading Down 2.2 %

Shares of PRLD stock opened at $0.95 on Wednesday. The company has a market capitalization of $52.21 million, a PE ratio of -0.53 and a beta of 1.37. The firm has a fifty day simple moving average of $1.10 and a 200-day simple moving average of $2.16. Prelude Therapeutics has a twelve month low of $0.80 and a twelve month high of $6.80.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Prelude Therapeutics in a research note on Friday, November 8th. JMP Securities reiterated a “market outperform” rating and set a $4.00 price objective (down from $7.00) on shares of Prelude Therapeutics in a research note on Wednesday, December 11th.

Insider Buying and Selling at Prelude Therapeutics

In related news, insider Andrew Combs acquired 60,000 shares of Prelude Therapeutics stock in a transaction on Monday, December 23rd. The shares were purchased at an average cost of $1.37 per share, for a total transaction of $82,200.00. Following the purchase, the insider now directly owns 377,623 shares of the company’s stock, valued at $517,343.51. The trade was a 18.89 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Krishna Vaddi bought 100,000 shares of the company’s stock in a transaction on Wednesday, December 18th. The shares were acquired at an average cost of $0.93 per share, for a total transaction of $93,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 1,167,275 shares of the company’s stock, valued at $1,085,565.75. This trade represents a 9.37 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 198,075 shares of company stock worth $213,486 in the last ninety days. 62.80% of the stock is owned by insiders.

About Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.